Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2,285 INR
Change Today -50.30 / -2.15%
Volume 95.7K
NTCPH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

natco pharma ltd (NTCPH) Snapshot

Open
2,332
Previous Close
2,336
Day High
2,360
Day Low
2,270
52 Week High
04/7/15 - 2,710
52 Week Low
05/30/14 - 725.10
Market Cap
76.0B
Average Volume 10 Days
164.7K
EPS TTM
40.51
Shares Outstanding
33.2M
EX-Date
02/24/15
P/E TM
56.4x
Dividend
5.00
Dividend Yield
0.22%
Current Stock Chart for NATCO PHARMA LTD (NTCPH)

Related News

No related news articles were found.

natco pharma ltd (NTCPH) Related Businessweek News

No Related Businessweek News Found

natco pharma ltd (NTCPH) Details

NATCO Pharma Limited operates as a pharmaceutical company in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic segments, such as anti-neoplastics, anti-depressants, anti-migraine, anti- osteoporosis, anti-asthma, proton pump inhibitors, and therapeutic peptides. It also provides generic oncology products for the treatment of hematology and solid tumors under the brand names of Geftinat, Erlonat, Veenat, and Sorafenat. In addition, it provides formulations, such as Ondansetron, Anastrozole, Letrozole, Trihexyphenidyl, Cholorquine Phosphate, and Citalopram, as well as is engaged in the retail pharmacy business and contract manufacturing activities. The company was incorporated in 1981 and is headquartered in Hyderabad, India.

Founded in 1981

natco pharma ltd (NTCPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

natco pharma ltd (NTCPH) Key Developments

Natco Pharma Limited, Q4 2015 Earnings Call, May 25, 2015

Natco Pharma Limited, Q4 2015 Earnings Call, May 25, 2015

NATCO Pharma Limited Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

NATCO Pharma Limited announced audited consolidated earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, the company recorded net revenue of INR 204.0 million against INR 19,376.0 million during fourth quarter of 2014, posting an increase of 5.28%, quarter-on-quarter basis. The profits after tax were recorded as INR 544.4 million, which includes a deferred tax reversal. For the year, the company recorded net revenue of INR 8,401.8 million against INR 7,556.0 million for last year, reflecting a growth of 11.20%. The net profit after tax was INR 1,346.1 million. This includes two exceptional items: a decrease in profit on account of an extraordinary charge of INR 151.3 million due to a legal settlement and an increase in profit on account of a reversal of deferred tax liability of INR 311.7 million.

Natco Pharma Limited Reports Standalone and Consolidated Unaudited Earnings Results for the Fourth Quarter and Audited Earnings Results for the Year Ended March 31, 2015

Natco Pharma Limited reported standalone and consolidated unaudited earnings results for the fourth quarter and audited earnings results for the year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 1,656.2 million compared to INR 1,443.9 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 479.6 million compared to INR 296.8 million a year ago. Profit from ordinary activities before tax was INR 418.4 million compared to INR 329.3 million a year ago. Net profit from ordinary activities after tax was INR 340.7 million compared to INR 263.4 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 19.63 compared to INR 7.96 a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 6,645.0 million compared to INR 5,720.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,861.2 million compared to INR 1,597.9 million a year ago. Profit from ordinary activities before tax was INR 1,544.1 million compared to INR 1,414.5 million a year ago. Net profit from ordinary activities after tax was INR 1,218.9 million compared to INR 1,101.9 million a year ago. Diluted earnings per share before and after extraordinary items were INR 46.17 compared to INR 34.49 a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 1,905.7 million compared to INR 1,748.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 366.6 million compared to INR 292.9 million a year ago. Profit from ordinary activities before tax was INR 304.9 million compared to INR 318.3 million a year ago. Net profit from ordinary activities after tax was INR 232.7 million compared to INR 240.2 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 16.41 compared to INR 7.26 a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 7,420.0 million compared to INR 6,884.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,661.1 million compared to INR 1,488.9 million a year ago. Profit from ordinary activities before tax was INR 1,342.1 million compared to INR 1,289.8 million a year ago. Net profit from ordinary activities after tax was INR 1,346.1 million compared to INR 1,027.4 million a year ago. Diluted earnings per share before and after extraordinary items were INR 40.64 compared to INR 32.16 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTCPH:IN 2,285.40 INR -50.30

NTCPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Momenta Pharmaceuticals Inc $19.38 USD -0.50
Teva Pharmaceutical Industries Ltd $59.97 USD -1.08
View Industry Companies
 

Industry Analysis

NTCPH

Industry Average

Valuation NTCPH Industry Range
Price/Earnings 56.3x
Price/Sales 3.9x
Price/Book 3.8x
Price/Cash Flow 50.5x
TEV/Sales 8.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATCO PHARMA LTD, please visit www.natcopharma.co.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.